BioCentury | Apr 30, 2020
Deals

Adicet to become public company via resTORbio merger

...CAR-T cell therapy targeting CD20. The companies said the merged entity will also develop an mTORC1...
...Adicet raised $80 million in October (see “OrbiMed leads series B” ). Targets mTORC1 - Mammalian target of rapamycin complex 1 Paul...
BioCentury | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

...China. In 2017, Celgene Corp. spun out Antengene Corp. with Chinese and Taiwanese rights to mTORC1...
...from BioCentury’s BCIQ database. Targets ALDOS (CYP11B2) - Aldosterone synthase KRAS - K-Ras mTORC1 - Mammalian target of rapamycin complex 1...
BioCentury | Nov 15, 2019
Clinical News

resTORbio drops respiratory infection program as it looks ahead to Parkinson’s readout

...it failed the pivotal PROTECTOR 1 trial, but the company is moving forward with the mTORC1...
...a stake in the company, which it gained when it exclusively licensed RTB101 and another mTORC1...
...wasn’t part of its strategy. Targets: mTORC1 - mammalian target of rapamycin complex 1 Sandi Wong, Staff Writer RTB101 resTORbio Inc. PureTech Health plc Mammalian target of rapamycin complex 1 (mTORC1...
BioCentury | Oct 4, 2019
Finance

Selectivity sets off $37M series A for mTOR company Aeovian

...Preclinical selectivity data for Aeovian’s mTORC1 inhibitor prompted venBio and Sofinnova Investments to co-lead the biotech’s...
...mTORC1 - Mammalian target of rapamycin complex 1; mTORC2 - Mammalian target of rapamycin complex 2 Elizabeth S. Eaton, Staff Writer venBio Sofinnova Investments Mammalian target of rapamycin complex 1...
...Mammalian target of rapamycin complex 1; mTORC2 - Mammalian target of rapamycin complex 2 Elizabeth S. Eaton, Staff Writer venBio Sofinnova Investments Mammalian target of rapamycin complex 1 (mTORC1) Mammalian...
BioCentury | Sep 13, 2019
Clinical News

Sept. 12 Clinical Quick Takes: Celgene meets in Phase III for AML maintenance therapy; plus Roche, Tocagen, Adverum, Daiichi Sankyo, Apple, Navitor

...Heart and Movement Study; and with University of Michigan for the Apple Hearing Study. Navitor's mTORC1...
...Epidermal growth factor receptor; HER3 (ERBB3; EGFR3) - Erb-b2 receptor tyrosine kinase 3; mTORC1 - Mammalian target of rapamycin complex 1...
...Co. Ltd. Navitor Pharmaceuticals Inc. Celgene Corp. Erb-b2 receptor tyrosine kinase 3 (HER3) (ERBB3) (EGFR3) Neurofilament light (NEFL) (NF-L) Mammalian target of rapamycin complex 1 (mTORC1) Apple...
BioCentury | Jul 9, 2019
Finance

Revolution raises $100M to build out Ras pipeline, explore SHP-2 combos

...and downstream targets of Ras -- the Phase I/II SHP-2 inhibitor RMC-4630 and a preclinical mTORC1...
...Targets: HRAS - v-Ha-ras Harvey rat sarcoma viral oncogene homolog; KRAS - K-Ras; mTORC1 - Mammalian target of rapamycin complex 1...
...homology protein tyrosine phosphatase 2 Allison Johnson, Senior Writer AMG 510 MRTX849 RMC-4630 Amgen Inc. Mirati Therapeutics Inc. Revolution Medicines Inc. Sanofi K-Ras (KRAS) Mammalian target of rapamycin complex 1 (mTORC1) Neuroblastoma...
BioCentury | Jun 20, 2019
Targets & Mechanisms

Moving beyond the active site: why allostery is newly in fashion

...tumors Phase I Src homology protein tyrosine phosphatase 1 (SHP-1; SHPTP1; PTPN6) Cancer Preclinical Mammalian target of rapamycin complex 1 (mTORC1...
...Calif. Sanofi (Euronext:SAN; NASDAQ:SNY), Paris, France Vividion Therapeutics Inc., San Diego, Calif. Targets mTORC1 - Mammalian target of rapamycin complex 1...
...Therapeutics Inc. Evotec SE GT Gain Therapeutics S.A. HotSpot Therapeutics Inc. Novartis AG Relay Therapeutics Inc. Revolution Medicines Inc. Vividion Therapeutics Inc. Mammalian target of rapamycin complex 1 (mTORC1) Src...
BioCentury | Jun 7, 2019
Distillery Therapeutics

Navitor’s mTORC1 activator for depression

...DISEASE CATEGORY: Neurology INDICATION: Depression Rat studies identified an mTORC1 activator that could help treat depression...
...Pharmaceuticals Inc. includes Phase I testing of NV-5138 in patients with treatment-resistant depression. TARGET/MARKER/PATHWAY: Mammalian target of rapamycin complex 1 (mTORC1...
...CONTACT: Ronald S. Duman, Yale University, New Haven, Conn. email: ronald.duman@yale.edu Claire Quang NV-5138 Navitor Pharmaceuticals Inc. Yale University Mammalian target of rapamycin complex 1 (mTORC1) Depression...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...Phosphodiesterase 4D interacting protein (PDE4DIP) Melanoma Deleterious events in PDE4DIP, a negative regulator of mammalian target of rapamycin complex 1 (mTORC1...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

...ACLY, the nucleotide depleting enzyme SAMHD1, and DEPDC5, an inhibitor of the amino acid sensor MTORC1...
...MicroRNA-17-92 MSI1 - Musashi RNA-binding protein 1 MSI2 - Musashi homolog 2 mTORC1 - Mammalian target of rapamycin complex 1...
Items per page:
1 - 10 of 89